Tirzepatide Cash Price in 2026: LillyDirect, Compounded, and Insurance Paths

You open the pharmacy app, type in "tirzepatide," and the number that comes back is $1,069 a month. That figure is real. It is the approximate list price for Mounjaro — one of the two branded forms of tirzepatide — without any savings program applied. For Zepbound, the weight-management version, the cash register reads roughly $1,086 for a 28-day supply at retail.

Those numbers are not, however, what most self-pay patients actually spend in May 2026. What you pay depends entirely on which of the three access lanes you are in: manufacturer direct, insurance-plus-savings-card, or the legally narrowed compounded market. Each lane has a very different price point, a different set of eligibility requirements, and a different degree of certainty about its future.

This is the dated price map for all three.

What tirzepatide is — and why the brand name matters for pricing

Tirzepatide is a dual GIP and GLP-1 receptor agonist manufactured exclusively by Eli Lilly. It exists under two brand names, and the brand you are prescribed determines which pricing programs you can access.

Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Mounjaro carries the same active molecule at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), but its FDA approval is for type 2 diabetes. Prescribers can and do prescribe it off-label for weight management, which is common when a patient already has a type 2 diabetes diagnosis and Mounjaro is covered by their insurer.

The brand distinction matters because Lilly's self-pay discount program, savings cards, and the upcoming Medicare bridge are all brand-specific. Zepbound has the direct cash-pay pathway. Mounjaro has the T2D savings card. They are not interchangeable at the pharmacy counter.

The headline prices in May 2026

The table below summarizes the main pricing tiers as of May 28, 2026.

Sources: Eli Lilly pricing information (May 2026); Lilly KwikPen self-pay announcement (February 23, 2026); CMS Medicare GLP-1 Bridge.

The LillyDirect lane: $299–$449 a month

The most significant development in tirzepatide cash pricing over the past eighteen months has been Eli Lilly's decision to sell directly to patients at a compressed margin.

On December 1, 2025, Lilly cut LillyDirect Self Pay prices for the Zepbound single-dose vial to $299 per month for the 2.5 mg starter, $399 per month for 5 mg, and $449 per month for 7.5 mg through 15 mg (Lilly investor release). The previous tier had been $349 for 2.5 mg and $499 for 5 mg, with higher doses unavailable via the vial channel.

On February 23, 2026, Lilly extended the identical $299/$399/$449 tier to the Zepbound KwikPen, its pre-filled multi-dose auto-injector (Lilly media statement). For the first time, patients had a choice of delivery format at the same price point. The vial requires drawing the medication into a syringe; the KwikPen is a click-and-inject device. Both deliver the same drug. The difference is operational, not pharmacological.

How the LillyDirect program works: Your prescriber writes a prescription for Zepbound. You either have it sent directly to LillyDirect Pharmacy or request a transfer. You pay at checkout on the LillyDirect platform. For 2.5 mg and 5 mg, the price holds without any refill-timing condition. For doses 7.5 mg and above, you must complete each refill within 45 days of the previous delivery to retain the $449 ceiling; miss that window and the purchase reverts to a higher price tier. A valid US prescription is required — LillyDirect does not fill prescriptions from outside the United States. The complete LillyDirect Zepbound enrollment walkthrough covers the sign-up steps in detail.

What LillyDirect does not cover: Mounjaro. The manufacturer direct self-pay channel is Zepbound-only. Patients who have been prescribed Mounjaro for type 2 diabetes and want to use it off-label for weight management cannot route that prescription through LillyDirect for the discounted tier.

The insurance lane: $25 a month, with conditions

Both Mounjaro and Zepbound carry manufacturer savings cards that can bring the monthly out-of-pocket cost to $25 for eligible commercially-insured patients.

The Zepbound savings card applies when a commercial insurance plan covers Zepbound. In that case, Lilly pays the difference between the plan's cost-sharing and $25, up to a $1,300 annual cap. If your commercial plan does not cover Zepbound, the savings card redirects you to LillyDirect Self Pay pricing rather than a flat cash price at retail.

The Mounjaro savings card follows the same structure for T2D-indicated prescriptions: $25 per 1-month, 2-month, or 3-month fill when commercial insurance covers the drug. Without coverage, the card provides $499 for a 1-month prescription — better than retail list but still a substantial monthly expense.

Both savings cards explicitly exclude Medicare, Medicaid, Veterans Affairs, and TRICARE beneficiaries. This is a compliance condition imposed by federal anti-kickback statute, not a Lilly policy choice.

Insurance coverage for Zepbound for weight management remains limited. Surveys cited by GoodRx (updated 2026) suggest that roughly 20–25% of commercial plans include weight-management GLP-1s in their formularies. Employer-sponsored plans are increasingly adding coverage, but prior authorization — typically requiring documented BMI plus failed trial of lifestyle intervention — is nearly universal when coverage exists.

The Mounjaro T2D path is worth noting for patients who carry a type 2 diabetes diagnosis. Mounjaro for T2D has broader commercial insurance coverage than Zepbound for weight management, because the T2D indication has been in formularies longer and the clinical value evidence is more established. A patient with both obesity and T2D may find that Mounjaro is covered where Zepbound is not — but the off-label weight-management use must be discussed with the prescriber, and insurers may audit claims.

The Medicare lane: $50 a month from July 1, 2026

Until mid-2026, Medicare beneficiaries were largely locked out of tirzepatide for weight management. Federal statute (the Medicare Prescription Drug, Improvement, and Modernization Act of 2003) historically prohibited Part D from covering drugs whose primary indication is weight loss. Mounjaro is covered for T2D through standard Part D, subject to plan formulary, but that route requires a T2D diagnosis.

That changes on July 1, 2026, when CMS launches the Medicare GLP-1 Bridge demonstration. Under this program, eligible Medicare Part D beneficiaries can access the Zepbound KwikPen for $50 per 30-day supply through December 31, 2027 (CMS program page).

Key restrictions: The bridge covers only the Zepbound KwikPen, not the single-dose vial. It requires a BMI of 35 or higher without additional criteria, or BMI 27 or higher with qualifying clinical criteria. Not all Part D plans participate; beneficiaries need to verify coverage during the annual enrollment period or through CMS's Medicare Plan Finder.

The $50 bridge copay is notably higher than the $25 savings card available to commercially-insured patients, but it represents the first time Medicare has broadly funded tirzepatide for weight management outside of the T2D indication.

The compounded lane: legally narrowed, still operating

In 2023 and 2024, compounded tirzepatide from 503A and 503B pharmacies became the dominant access route for cash-pay patients priced out of branded options. Monthly costs ranged from $150 to $500 depending on dose and provider, and telehealth platforms built subscription businesses around it.

That model broke against a regulatory timeline:

• October 2, 2024: FDA officially declared the tirzepatide drug shortage resolved.
• February 18, 2025: FDA's enforcement-discretion period for 503A compounding pharmacies expired.
• March 19, 2025: Enforcement-discretion period for 503B outsourcing facilities expired.
• May 2025: Federal court upheld FDA's decision removing tirzepatide from the shortage list, ending a legal challenge by compounding pharmacy trade groups.

The statutory result: routinely producing copies of FDA-approved tirzepatide products is no longer legally permissible under the shortage exception. 503B outsourcing facilities cannot bulk-compound tirzepatide. The broad compounding market that served hundreds of thousands of patients has been legally foreclosed.

What remains — and this is where the situation is genuinely contested — is a narrow provision under §503A(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act, which allows a licensed compounding pharmacist to prepare a drug product that differs from an FDA-approved drug if there is a documented clinical need for a variation that the approved product cannot provide. Some 503A pharmacies have reframed their tirzepatide compounding as patient-specific formulations — for example, adding B vitamins or adjusting concentration — under this provision. Whether that framing satisfies the statutory standard is legally contested and subject to ongoing FDA and state board enforcement.

Patients who see telehealth platforms advertising compounded tirzepatide in mid-2026 are almost certainly encountering this §503A(b)(1)(D) framing. The risks are real: no FDA oversight of individual batches, variable potency, no clinical trial data on the compound-plus-additive formulation, and potential legal exposure for the prescriber if the documented clinical need does not withstand scrutiny. Your prescriber is the right person to discuss whether this path makes sense for your specific situation.

For context on actual prices still being quoted: a number of Reddit commenters in early 2026 were reporting compounded tirzepatide from remaining providers in the $200–$350/month range, flat across doses — a pricing structure the branded market cannot match at higher doses. One thread in r/Ozempic from January 2026 noted prices of approximately $200–$300 per month from telehealth providers still operating, with commenters flagging the legal shift but noting the programs were "still running." The landscape is moving faster than search results reflect.

The FSA/HSA lever

One cost-reduction tool that applies across all three lanes is the health savings account (HSA) or flexible spending account (FSA). Tirzepatide is an HSA/FSA-eligible expense. Purchasing LillyDirect Self Pay medication through an HSA or FSA card effectively reduces the after-tax cost by your marginal federal income tax rate — roughly 22% for a household earning $80,000–$170,000, which moves the $449/month ceiling to roughly $350 in after-tax dollars. Reddit users in r/Ozempic have flagged this strategy repeatedly, including one thread from August 2025 where a poster outlined using an FSA combined with a 2x-dose pen strategy to push the annual cost below $2,000.

Lilly Cares: the assistance path for very low income

Patients who fall below the savings-program eligibility floor — typically those without any commercial insurance and with income below 400% of the federal poverty level — may qualify for the Lilly Cares Foundation patient assistance program, which provides free Mounjaro or Zepbound to qualifying patients. The program requires prescriber enrollment and income documentation. This route moves slowly but can eliminate cost entirely for qualifying individuals.

How the paths compare: a decision framework

The practical decision most self-pay patients face is simpler than the full landscape suggests:

If you have commercial insurance that covers Zepbound or Mounjaro: Use the manufacturer savings card. Your prescriber's office can help you check formulary coverage and submit prior authorization. Monthly cost can reach $25.

If you have commercial insurance that does not cover either brand: LillyDirect Self Pay for Zepbound is the clearest path. You pay $299–$449 per month depending on your prescribed dose, with no insurer prior authorization required on the Lilly side (your prescriber still makes the clinical determination).

If you are on Medicare: Starting July 1, 2026, the GLP-1 Bridge offers $50/month for the KwikPen if you meet BMI criteria and your plan participates. Verify eligibility through Medicare Plan Finder before the July 1 start date.

If you have a type 2 diabetes diagnosis alongside obesity: Discuss Mounjaro with your prescriber. The T2D indication has broader commercial formulary coverage and the $25 savings card applies when the plan covers it. This is a clinical conversation about indication, not a patient-initiated formulary arbitrage.

If you are weighing compounded options: Understand that the legal basis is narrow and contested. The price differential versus LillyDirect is shrinking as Lilly has reduced cash prices twice in twelve months. The calculation looks different than it did in 2023.

What to watch

For a head-to-head look at how tirzepatide compares to semaglutide on efficacy, see our tirzepatide vs semaglutide comparison.

Tirzepatide pricing is not stable. Lilly cut LillyDirect prices twice in the twelve months ending February 2026. The Trump administration reached a November 2025 Most-Favored-Nation framework with Lilly and Novo Nordisk signaling potential further downward pressure on list prices through government programs. The Medicare bridge program, which begins in July 2026, will generate utilization data that may influence future Medicare coverage decisions. And the ongoing federal litigation around 503A compounding means the compounded landscape could clarify — in either direction — without much notice.

The prices in this article were verified against Lilly's official pricing information page (pricinginfo.lilly.com/zepbound) and the Lilly investor relations announcements cited above. We update this article on every Lilly pricing change and every Material update to the Medicare GLP-1 Bridge.

This article is editorial and informational. It is not medical advice. Your prescriber determines whether tirzepatide is appropriate for you, at what dose, and under which indication. Metabolic Ledger has no financial relationship with Eli Lilly, any telehealth provider, or any compounding pharmacy.